Circulating FABP4 is a prognostic biomarker in patients with acute coronary syndrome but not in asymptomatic individuals
Hans Reiser, Roland Klingenberg, Danielle Hof, Seraina Cooksley-Decasper, Nina Fuchs, Alexander Akhmedov, Stefan Zoller, Pedro Marques-Vidal, Helena Marti Soler, Dik Heg, Ulf Landmesser, Nicolas Rodondi, Francois Mach, Stephan Windecker, Peter Vollenweider, Christian M Matter, Thomas F Lüscher, Arnold von Eckardstein, Joanna Gawinecka, Hans Reiser, Roland Klingenberg, Danielle Hof, Seraina Cooksley-Decasper, Nina Fuchs, Alexander Akhmedov, Stefan Zoller, Pedro Marques-Vidal, Helena Marti Soler, Dik Heg, Ulf Landmesser, Nicolas Rodondi, Francois Mach, Stephan Windecker, Peter Vollenweider, Christian M Matter, Thomas F Lüscher, Arnold von Eckardstein, Joanna Gawinecka
Abstract
Objective: Blood-borne biomarkers reflecting atherosclerotic plaque burden have great potential to improve clinical management of atherosclerotic coronary artery disease and acute coronary syndrome (ACS).
Approach and results: Using data integration from gene expression profiling of coronary thrombi versus peripheral blood mononuclear cells and proteomic analysis of atherosclerotic plaque-derived secretomes versus healthy tissue secretomes, we identified fatty acid-binding protein 4 (FABP4) as a biomarker candidate for coronary artery disease. Its diagnostic and prognostic performance was validated in 3 different clinical settings: (1) in a cross-sectional cohort of patients with stable coronary artery disease, ACS, and healthy individuals (n=820), (2) in a nested case-control cohort of patients with ACS with 30-day follow-up (n=200), and (3) in a population-based nested case-control cohort of asymptomatic individuals with 5-year follow-up (n=414). Circulating FABP4 was marginally higher in patients with ST-segment-elevation myocardial infarction (24.9 ng/mL) compared with controls (23.4 ng/mL; P=0.01). However, elevated FABP4 was associated with adverse secondary cerebrovascular or cardiovascular events during 30-day follow-up after index ACS, independent of age, sex, renal function, and body mass index (odds ratio, 1.7; 95% confidence interval, 1.1-2.5; P=0.02). Circulating FABP4 predicted adverse events with similar prognostic performance as the GRACE in-hospital risk score or N-terminal pro-brain natriuretic peptide. Finally, no significant difference between baseline FABP4 was found in asymptomatic individuals with or without coronary events during 5-year follow-up.
Conclusions: Circulating FABP4 may prove useful as a prognostic biomarker in risk stratification of patients with ACS.
Trial registration: ClinicalTrials.gov NCT01000701.
Keywords: FABP4 protein, human; acute coronary syndrome; atherosclerosis; biological markers; follow-up studies.
© 2015 American Heart Association, Inc.
Source: PubMed